William Blair Has Pessimistic Outlook of BMRN Q1 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at William Blair lowered their Q1 2025 earnings estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Monday, April 14th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings per share of $0.77 for the quarter, down from their previous forecast of $0.85. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. William Blair also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $3.47 EPS and FY2026 earnings at $4.33 EPS.

A number of other research firms have also recently weighed in on BMRN. Citigroup boosted their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price on the stock in a research note on Monday, February 24th. Royal Bank of Canada reiterated a “sector perform” rating and set a $70.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, Wedbush restated an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

BioMarin Pharmaceutical Price Performance

BMRN opened at $59.17 on Thursday. BioMarin Pharmaceutical has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The firm has a 50-day moving average of $66.83 and a 200 day moving average of $66.35. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The firm has a market cap of $11.29 billion, a P/E ratio of 26.90, a PEG ratio of 0.61 and a beta of 0.30.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in shares of BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 211 shares in the last quarter. LRI Investments LLC raised its position in BioMarin Pharmaceutical by 856.9% during the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 437 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in BioMarin Pharmaceutical during the fourth quarter valued at about $36,000. MassMutual Private Wealth & Trust FSB lifted its stake in BioMarin Pharmaceutical by 71.2% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 218 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 233 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the transaction, the chief accounting officer now owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. The trade was a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.